Gabapentin is an anticonvulsant prescribed off-label for insomnia at roughly 100mg to 600mg at bedtime, and it is one of the few sleep agents shown to increase slow-wave sleep. Its evidence base for primary insomnia is limited, with most positive data coming from restless legs syndrome, alcohol withdrawal, and menopausal hot flashes. The FDA issued a warning in 2019 about serious breathing difficulties when gabapentinoids are combined with opioids or other central nervous system depressants or used by people with respiratory risk factors, and abrupt discontinuation after sustained use can cause a withdrawal syndrome. Fishtown Medicine prescribes it in Pennsylvania and New Jersey only, with an in-person evaluation every six months.
TL;DR: Gabapentin is a seizure and nerve-pain medicine that also increases deep sleep, which is unusual and useful for some people. It is used off-label at bedtime, usually 100mg to 600mg. It deserves more caution than it typically gets. The FDA warned in 2019 that gabapentin can cause serious breathing problems when combined with opioids or other sedating drugs, or in people with lung disease. Stopping it suddenly after months can cause a withdrawal syndrome. Several states have made it a controlled substance because it is misused. Because of all that, this practice prescribes it in Pennsylvania and New Jersey only, with an in-person visit every six months. If you are on it and it was never really explained, that is worth a conversation. Tell Dr. Ash.
Gabapentin is prescribed for an enormous range of things, many of them off-label, and sleep is one of the commonest.
It also carries a set of concerns that have grown clearer over the past decade, which is why it is treated here as a medication with a tether attached.
How does gabapentin affect sleep?
It binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters. Despite the name, it does not act on GABA receptors.
The interesting part for sleep is what that does to sleep architecture. Gabapentin has been shown to increase slow-wave sleep, the deep stage associated with physical restoration and memory consolidation. That is unusual: most sedating drugs, including the benzodiazepines and to a degree the Z-drugs, reduce slow-wave sleep while producing the subjective sense of having slept.
A drug that adds deep sleep instead of subtracting it is a strong point in its favour, and it is why gabapentin keeps coming up in conversations about sleep quality as opposed to sleep quantity.
What dose is used, and how good is the evidence?
Typically 100mg to 600mg at bedtime, started low and taken one to two hours before sleep.
The evidence for primary insomnia is limited. Most of the supportive data comes from specific populations: restless legs syndrome, where gabapentin enacarbil holds FDA approval; alcohol withdrawal and early recovery, where it improves sleep meaningfully; menopausal hot flashes, where it reduces night-time waking; and neuropathic pain, where better sleep follows from less pain.
The AASM pharmacologic guideline did not evaluate gabapentin for chronic insomnia, so there is no formal recommendation either way. That is a gap and not an endorsement.
What follows practically is that gabapentin makes most sense for insomnia with a specific comorbid driver it also treats, and much less sense as a general-purpose sleep aid.
Guidance from the Clinic
What is the breathing warning?
In December 2019 the FDA required new warnings about serious breathing difficulties with gabapentinoids, meaning gabapentin and pregabalin, in people at higher respiratory risk.
The groups named are people also taking opioids or other central nervous system depressants including benzodiazepines, people with underlying respiratory disease such as COPD, and older adults. The concern is respiratory depression, and in the reported cases it was serious.
The practical reading: gabapentin is not a benign addition to a medication list that already contains something sedating. Anyone taking an opioid, a benzodiazepine, a Z-drug, or a sedating antihistamine, and anyone with COPD or another significant lung condition, needs this weighed properly. So does anyone with untreated sleep apnea, which is the case for a large number of people who have never been tested, and which is covered on insomnia or sleep apnea.
What about misuse and withdrawal?
Both are documented, and both were underappreciated for a long time.
Evidence-Based Treatment
Dr. Ash reviews the research - and applies it to your specific biology.
Misuse. Gabapentin has recognized misuse potential, concentrated in people with a history of substance use disorder and particularly alongside opioids, where it can potentiate the effect. Several states have scheduled it as a controlled substance in response, and many others require reporting to prescription monitoring programs. It is not a federally scheduled drug.
Withdrawal. Stopping abruptly after sustained use can produce anxiety, insomnia, nausea, sweating, tremor, and in rare cases seizures. The insomnia rebound is particularly relevant here, since somebody taking it for sleep who stops suddenly gets several nights that are worse than where they started, which is how people conclude they cannot manage without it. A taper over one to two weeks, longer at higher doses, avoids most of it.
What are the other side effects?
Dizziness and drowsiness, the commonest, and dose-related.
Unsteadiness and falls, which matter most in older adults and are the reason to start low.
Peripheral swelling, in the ankles and feet, sometimes marked.
Weight gain, common enough over months that it belongs in the first conversation.
Cognitive fog, described as difficulty finding words or feeling slowed, more at higher doses.
Gabapentin is cleared by the kidneys, so anyone with reduced kidney function needs a lower dose. That is a routine check and it is often missed when a prescription is written quickly.
How Fishtown Medicine prescribes it
In Pennsylvania and New Jersey only, with an in-person evaluation every six months, and with the reasoning documented.
Gabapentinoids sit in the tethered group in this practice's prescribing policy, alongside DEA-controlled substances, because of the scheduling in some states, the misuse and dependence potential, and the sedation risk that compounds with other agents. Nothing about that discourages the prescription where it is right. It requires that there be a written reason: what was tried, what it is treating, what the monitoring plan is, and when the next in-person visit falls.
For somebody whose insomnia comes with restless legs, neuropathic pain, or menopausal night waking, gabapentin can be a good answer that treats two problems at once. For somebody with uncomplicated chronic insomnia and no comorbid driver, CBT-I is the better first move and the guidelines agree.
Key Takeaways
- Gabapentin increases slow-wave sleep, which most sedating drugs reduce, and that is its strongest argument.
- Its evidence for uncomplicated insomnia is limited, with most positive data from restless legs, alcohol withdrawal, and hot flashes.
- The FDA's 2019 warning covers serious breathing difficulties with opioids, other sedatives, respiratory disease, and older age.
- Abrupt stopping after sustained use causes withdrawal, including rebound insomnia severe enough to look like dependence.
- Fishtown Medicine prescribes it in Pennsylvania and New Jersey only, with an in-person evaluation every six months.
Related at Fishtown Medicine
Scientific References
- US Food and Drug Administration. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin and pregabalin. Drug Safety Communication, December 2019.
- Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, Mascha E, Dinner D, Morris HH. Gabapentin increases slow-wave sleep in normal adults. Epilepsia. 2002;43(12):1493-1497.
- Furey SA, Hull SG, Leibowitz MT, Jayawardena S, Roth T. A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia. Journal of Clinical Sleep Medicine. 2014;10(10):1101-1109.
- Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160-1174.
- Mersfelder TL, Nichols WH. Gabapentin: Abuse, Dependence, and Withdrawal. Annals of Pharmacotherapy. 2016;50(3):229-233.
- US Food and Drug Administration. Neurontin (gabapentin) prescribing information. FDA Access Data.
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.